Optimizing Biologic Selection in Severe Asthma: Integrating Guidelines, Equity, and Patient-Centered Care

LIVE MEETINGS
up to 1.25 AMA PRA Credit
This educational activity is supported by an independent educational grant from GSK.

Maximum Credit Amount: 1.25

Credit Type: ACCME, ANCC
Release: August 1, 2026
Expiration: September 17, 2026

To view the AI Simulation and claim credit, click the "Get CME Credit" to log in or create your free account.

Live Meetings
Overview
Learning Objectives
CME/ Information
Faculty and Disclosures
Instructions
Southeastern Allergy, Asthma & Immunology Society Annual Conference
Hilton Head Island, SC
The Omni Hilton Head
Palmetto Ballroom
6:00 pm - 7:00 pm EST

September

17

2026

Attending SEAAIS? Pre-register for this CME session. Conference registration is required to attend.
2026 Southern California
Allergy Conference

Oceanside, CA
The Seabird Resort

 

October

18

2026

September

17

2026

Southeastern Allergy, Asthma & Immunology Society Annual Conference
Hilton Head Island, SC
The Omni Hilton Head
Palmetto Ballroom
6:00 pm - 7:00 pm EST

October

18

2026
Southern California
Allergy Conference
Oceanside, CA
The Seabird Resort
Room TBD
Time TBD

To view the AI Simulation and claim credit, click the "Get CME Credit" to log in or create your free account.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • Utilize understanding of severe asthma pathophysiology encompassing Type 2 inflammatory pathways, IL-5-mediated mechanisms, and biomarker-based phenotypic classification to guide precision medicine approaches in clinical practice.  
  • Employ biomarker-driven phenotyping approaches to determine appropriate candidates for biologic therapies, integrating recommendations from the GINA 2025 and CHEST 2025 guidelines along with novel therapeutic agents.  
  • Implement collaborative decision-making techniques that ensure biologic therapy selections reflect individual patient priorities and preferences within the context of severe asthma management.  
  • Apply systematic approaches for identifying and addressing comorbid conditions as part of an individualized treatment plan for patients living with severe asthma.  
  • Recognize social determinants of health that influence severe asthma outcomes.  
  • Develop actionable strategies to address inequities in care delivery. 

Accredited Provider

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Global Education Group and Iridium CE. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation

Global Education Group designates this live material for a maximum of 1.25 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Contact Hours Designation

Global Education Group designates this continuing education activity for 1.25 contact hour(s) including 0.0 pharmacotherapeutic contact hour(s).

Faculty, Staff, and Planners’ Disclosures

Name of Planner or Manager Reported Financial Relationship
Conor Hughes Nothing to disclose
Andrea Funk Nothing to disclose
Ashley Cann Nothing to disclose
Lauren Sinclair Nothing to disclose
Deborah Sharkey Nothing to disclose
Rhys Williams, MSN, FNP-C, RN
(Nurse Planner)		 Nothing to disclose 
Alyssa Rossi Nothing to disclose
Monique Walters Nothing to disclose
Melissa Wiles Nothing to disclose 
Adriana Szelenski Nothing to disclose 
Mandy Comeau Nothing to disclose 
Nirupama Mulherkar Nothing to disclose 
Michael S. Blaiss, MD
(Faculty Chair)		 Consulting Fee (e.g., Advisory Board): AstraZeneca, Bayer, Begin Health, GSK, Kenvue, Lilly, Nasus Pharma, Novartis, Ophelia, Regeneron, Sanofi

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium CE do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosures of Relevant Financial Relationship(s)

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
IWAA faculty Presenter:
Suzanne Ngo, MD
Assistant Professor
Department of Medicine-Allergy/Clinical Immunology
University of Colorado
Aurora, CO

Disclosures
Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): 
AbbVie, Inc., Alnylam Pharmaceuticals, Inc., Amgen, Inc.,Biogen, Inc., Bristol Myers Squibb Co., Gilead Sciences, Inc., Incyte Corp., Kenvue, Inc., Eli Lilly & Co., Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., Viatris, Inc., Align Technology, Inc., Becton, Dickinson & Co., Boston Scientific Corp., Edwards Lifesciences Corp., GE Healthcare Technologies, Inc., Intuitive Surgical, Inc., Johnson & Johnson, Insulet Corp., ResMed, Inc., Solventum Corp., STERIS Plc, West Pharmaceutical Services, Inc., Quest Diagnostics, Inc., Danaher Corp., Labcorp Holdings, Inc., Revvity, Inc., Bio-Techne Corp., Thermo Fisher Scientific, Inc., Waters Corp., Cardinal Health, Inc., Cencora, Inc., CVS Health Corp., Henry Schein, Inc., McKesson Corp.
SEAAIS faculty Presenter:
Michael S. Blaiss, MD
Clinical Professor
Allergy/Immunology and Rheumatology
Medical College of Georgia at Augusta University
Augusta, GA

Disclosures
Consulting Fee (e.g., Advisory Board):
AstraZeneca, Bayer, Begin Health, GSK, Kenvue, Lilly, Nasus Pharma, Novartis, Ophelia, Regeneron, Sanofi
SDAS faculty Presenter:


Disclosures

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the activity, application for credit and evaluation form. Participants must also score at least 70% on the post-test. 

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Global Contact Information

For information about the Joint Accreditation, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

System Requirements

System requirements

Program Overview

Optimizing Biologic Selection in Severe Asthma: Integrating Guidelines, Equity, and Patient-Centered Care is a live CME/CE activity designed to improve clinician competence in biomarker-guided phenotyping, biologic selection, shared decision-making, and equitable severe asthma care. Through expert faculty education and immersive Conversational AI patient simulations, learners will engage in interactive, case-based experiences focused on guideline-concordant treatment selection, comorbidity management, culturally competent communication, and individualized care strategies for patients with severe asthma.

Target Audience

The primary audience for this activity includes pulmonologists, critical care specialists, and allergists/immunologists, as well as nurse practitioners and physician assistants who specialize in the diagnosis and management of severe asthma.

Supporter Acknowledgement

This educational activity is supported by an independent educational grant from GSK.